Nano Dimension Faces Power Struggle Amid Activist Pressure
Israeli 3D printer manufacturer Nano Dimension is at the center of a corporate battle as activist fund Murchinson gains influence. The struggle centers on the company's significant cash reserves and the future of its strategic direction.
While most Israeli investors are focused on local market volatility or security developments regarding Iran, a significant corporate battle is unfolding quietly: an activist takeover of the veteran Israeli firm Nano Dimension (NNDM) by the Toronto-based fund Murchinson.
Nano Dimension, a manufacturer of 3D printers for electronic components, was once a high-profile tech stock on the NASDAQ. Murchinson has been pressuring the company for years, and its recent actions have brought the conflict to a head.
The Activist Campaign
In a single week, Murchinson purchased approximately 4.7 million shares at prices between $1.26 and $1.39, bringing its total holding to 20.3 million shares—just below the 10% threshold that would trigger the company's "poison pill" anti-takeover mechanism. This mechanism is designed to dilute hostile parties by issuing new shares at a discount.
By mid-July, the parties reached a settlement. CEO Yoav Stern, Chairman Robert Pons, and two other directors resigned, replaced by three candidates backed by the fund. Moshe Rosenbaum was appointed interim CEO, and Philip Bornstein became chairman. Effectively, Murchinson has taken the helm without a formal acquisition.
The Cash Gap
The fund's interest is driven by a financial anomaly: at the end of the first quarter, Nano Dimension held approximately $440 million in cash, while its market capitalization was only $312 million. Activist investors view this cash-to-market-value gap as an asset to be unlocked.
Nano Dimension's history has been tumultuous. After a 2014 reverse merger, it raised nearly $1.5 billion by early 2021. However, former CEO Yoav Stern's strategy to consolidate the 3D printing industry through acquisitions—including failed attempts to buy Stratasys and investments in Desktop Metal and Markforged—resulted in significant losses.
Current Outlook
In June, Nano Dimension signed a merger agreement with Infinite Epigenetics, an AI-based medical diagnostics firm, valued at $890 million. Murchinson condemned the deal as "flawed." The new board has since halted the Infinite deal, citing a need for "business continuity" and re-evaluation, while also considering an all-cash alternative offer from Tang Capital.
For investors, the stock is no longer a play on 3D printing technology, but a bet on the outcome of this control struggle. With a net loss of $69.7 million in the first quarter of 2026 and the withdrawal of its 2026 forecast, the company's future remains tied to which corporate strategy prevails.
